Research graph
References from Development and external validation of a simple pre-biopsy risk stratification model for clinically significant prostate cancer in men with PI-RADS 3 lesions: a multicenter transperineal biopsy study. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2
10.1016/j.eururo.2019.02.033 · 2019 · External reference
Unresolved reference
2026 · External reference
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level
10.1038/s41391-021-00417-1 · 2022 · External reference
Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative
10.1016/j.urolonc.2022.08.009 · 2022 · External reference
Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation
10.1111/bju.15277 · 2021 · External reference
MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions
10.21037/tau.2017.12.31 · 2018 · External reference
PI-RADS 3 lesions: a critical review and discussion of how to improve management
10.1007/s00261-023-03929-7 · 2023 · External reference
Diagnostic performance of prostate-specific antigen density for detecting clinically significant prostate cancer in the era of magnetic resonance imaging: a systematic review and meta-analysis
10.1016/j.euo.2023.08.002 · 2024 · External reference
Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making
10.1093/bjr/tqad027 · 2024 · External reference
Radiomics in PI-RADS 3 multiparametric MRI for prostate cancer identification: literature models re-implementation and proposal of a clinical-radiological model
10.3390/jcm11216304 · 2022 · External reference
Development and validation of a radiomics nomogram for predicting clinically significant prostate cancer in PI-RADS 3 lesions
10.3389/fonc.2021.825429 · 2022 · External reference
Magnetic resonance imaging radiomics-based prediction of clinically significant prostate cancer in equivocal PI-RADS 3 lesions in the transitional zone
10.3389/fonc.2023.1247682 · 2023 · External reference
Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions
10.1002/cam4.5100 · 2023 · External reference
Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging
10.62347/xbbi9870 · 2024 · External reference
Equivocal PI-RADS three lesions on prostate magnetic resonance imaging: risk stratification strategies to avoid MRI-targeted biopsies
10.3390/jpm10040270 · 2020 · External reference
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions
10.1038/s41391-024-00872-6 · 2025 · External reference
Comparison of the incidence of clinically significant prostate cancer in patients with isolated peripheral versus transitional zone PI-RADS 3 lesions
10.1177/03915603241286064 · 2025 · External reference
